The mission of the Department of Cellular Therapy and Cancer Research (CTCR) at KAIMRC is to improve the management of cancer, diabetes, cardiovascular and immunological diseases through high-quality and innovative research, teaching, and training.
CTCR department at KAIMRC has a team of scientists and several technologists advancing research in the following areas:
- Cellular Therapy
- Cancer
- Tissue Engineering
- Stem Cells and Regenerative Medicine.
The department has existing collaborations with national and international research organizations. We are also continuously striving to build new relationships within and outside KAIMRC through partnerships to establish a robust inter-disciplinary department.
Our vision is to serve humanity by generating high-quality research that can help improve a patient’s quality of life. Simultaneously, we are working towards developing prevention strategies to minimize the burden on healthcare systems.
Our institution has mandated precision and personalized medicine as the future of healthcare. We are working to fulfill that mandate by generating evidence using indigenous state-of-the-art technologies.
Research Focus Areas
Cellular Therapy and Cancer Research:
CTCR has identified three types of cancers based on tissue of origin – Breast, Colorectal, and blood. These are focused research areas aided by epigenetics, genomics, CAR-T cell technology, stem cell technology, signaling pathways, nanotechnology, cell, and molecular biology techniques.
Stem Cells and Regenerative Medicine:
Another focus area of CTCR is Stem cell research. We have a team of dedicated stem cell expert scientists whose goal is to utilize stem cells’ therapeutic properties against various diseases, including cancer and metabolic disorders. Stem cells possess pleiotropic properties that include immune-modulation, inhibition of apoptosis, fibrosis and oxidative stress, secretion of trophic factors, and enhancement of angiogenesis. Based on these properties, stem cells are widely used for the treatment of several diseases. We have made significant headway in many areas of treatment of these diseases. Currently, we are advancing our research to preclinical and clinical trials.